ArticleDiscover oncology2025
Changing patterns of colorectal cancer in China between 2000 and 2016 based on tertiary hospital data.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CircLRIG1 inhibits the malignant phenotypes of colorectal cancer cells by inactivating the NF-κB signaling through interaction with FUS.Discover oncology · 2026Article
- Is surgery necessary for mismatch repair-deficient/microsatellite instability-high colorectal cancer patients with a clinical complete response after neoadjuvant immunotherapy? A retrospective cohort study with literature context.World journal of surgical oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer ranks fourth globally in cancer-related deaths, causing about nine million annual fatalities. Developed countries show higher mortality rates due to factors like aging, diet, obesity, inactivity, and tobacco use. While colonoscopy initiatives reduce incidence, early-onset cases rise. China faces a significant colorectal cancer burden. This study examines post-2000 colorectal cancer trends in Chinese tertiary hospitals to guide future priorities. MATERIALS AND
methodsThis study, spanning 2000-2016, gathered colorectal cancer data from five Chinese tertiary hospitals. Patient details, including age, gender, colonoscopy findings, and pathology reports, were anonymized with unique serial numbers to protect privacy.
resultsThe overall incidence rate in females is approximately 2.9%, which is lower than the 3.2% in males (p < 0.05). Female patients have a lower average age compared to males (59.7 vs. 61.5, p < 0.01). Additionally, after 2008, there is a significant increase in the average age of patients compared to before 2008 (p < 0.001), and the proportion of female patients has significantly risen (p < 0.05). The preferred location for colon cancer has shifted from the distal end to the proximal end, and there is also an increase in the malignancy level.
conclusionFrom the perspective of tertiary hospitals, the pattern of colorectal cancer in China has undergone significant changes. The focus of diagnosis and treatment in tertiary hospitals in China should gradually shift toward the elderly patients, which helps address healthcare needs and is of significant importance for resource allocation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.